Skip to main content

Cancer and Blood

 Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours (NETs), Policy Position Statement (PP195), November 2026.pdf (PDF, 334Kb)
 Proton Beam Therapy for children, teenagers and young adults (TYA) with cancer, Commissioning Policy (CP148), April 2023.pdf (PDF, 231Kb)
 Radiofrequency Ablation (RFA) for the management of Barrett's Oesophagus in Adults, Commissioning Policy (CP183), June 2025.pdf (PDF, 532Kb)
 Radiofrequency Ablation (RFA) for the management of Barrett's Oesophagus in Adults, Service Specification (SS183), June 2025.pdf (PDF, 513Kb)
 Salvage Cryotherapy for Prostate Cancer, Policy Position Statement, (PP173), June 2020.pdf (PDF, 188Kb)
 Selective internal radiation therapies (SIRT) for treating adults with hepatocellular carcinoma (PPS227), Policy Position Statement, November 2021.pdf (PDF, 276Kb)
 Services for Children with Cancer, Service Specification (SS86), December 2024.pdf (PDF, 509Kb)
 Sickle Cell Disorders, Thalassaemia Disorders and other rare hereditary anaemias all ages, Service Specification (CP179), December 2020.pdf (PDF, 453Kb)
 Soft tissue sarcoma, Service Specification (SS149), November 2025 (PDF, 556Kb)
 Specialised Immunology, Service Specification (SS78), October 2024.pdf (PDF, 615Kb)
 Stereotactic ablative body radiotherapy (SABR) for patients aged 18 years old and above (PP278), Policy Position Statement, August 2026.pdf (PDF, 511Kb)
 Stereotactic ablative body radiotherapy (SABR) for patients aged 18 years old and above with (LANPC) (PP280), Policy Position Statement, August 2026.pdf (PDF, 371Kb)
 Stereotactic Ablative Body Radiotherapy (SABR) for patients with metachronous extracranial oligometastic cancer (all ages), Commissioning Policy (CP121), December 2024.pdf (PDF, 551Kb)
 Vonicog alfa for the treatment and prevention of bleeding in people of all ages with von Willebrand disease, Policy Position Statement (PP215), October 2023.pdf (PDF, 353Kb)